Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4.

Chen S, Liu AR, An FM, Yao WB, Gao XD

Age (Dordrecht, Netherlands)8 Sept 2011Cited by 106 (Europe PMC)

PMID21901364PMCIDPMC3448986DOI10.1007/s11357-011-9303-8PepBankPUB-21901364

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ICV-STZ-treated rats, twice-daily exendin‑4 improved Morris water maze learning and memory performance versus saline.
In plain wordsIn rats given ICV-STZ, exendin‑4 improved maze learning and memory performance compared with saline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLearning and memory performance
Study
ratn: not reported in source
ICV-STZ diabetes-related Alzheimer-like changes
Comparator
Saline
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Fourteen days following ICV-STZ injection, rats treated with twice-daily Ex-4 had better learning and memory performance in the Morris water maze test compared with rats treated with saline.
Report a problemFND-2190136404
02AnimalAnimal study (in vivo)Efficacy outcome
In ICV-STZ-treated rats, exendin‑4 protected hippocampal neurons against degeneration.
In plain wordsIn rats given ICV-STZ, exendin‑4 protected hippocampal nerve cells against degeneration.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHippocampal neuron degeneration
Study
ratn: not reported in source
ICV-STZ diabetes-related Alzheimer-like changes
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Additionally, histopathological evaluation confirmed the protective effects of Ex-4 treatment on hippocampal neurons against degeneration.
1 context sentence(design, population, supporting numbers)
Summary · context
In rat models, bilateral ICV-STZ administration was used to produce impaired insulin signaling in the brain.
Report a problemFND-2190136405
03AnimalAnimal study (in vivo)Mechanism
In ICV-STZ-treated rats, exendin‑4 reversed tau hyperphosphorylation.
In plain wordsIn rats given ICV-STZ, exendin‑4 reversed excessive tau phosphorylation.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTau hyperphosphorylation
Study
ratn: not reported in source
ICV-STZ diabetes-related Alzheimer-like changes
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, we demonstrated that Ex-4 reversed ICV-STZ-induced tau hyperphosphorylation through downregulation of GSK-3β activity, a key kinase in both DM and AD.
1 context sentence(design, population, supporting numbers)
Summary · context
In rat models, bilateral ICV-STZ administration was used to produce impaired insulin signaling in the brain.
Report a problemFND-2190136406
04AnimalAnimal study (in vivo)Mechanism
In ICV-STZ-treated rats, exendin‑4 downregulated GSK-3β activity as part of reversing tau hyperphosphorylation.
In plain wordsIn rats given ICV-STZ, exendin‑4 reduced GSK-3β activity as part of reversing excessive tau phosphorylation.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGSK-3β activity
Study
ratn: not reported in source
ICV-STZ diabetes-related Alzheimer-like changes
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, we demonstrated that Ex-4 reversed ICV-STZ-induced tau hyperphosphorylation through downregulation of GSK-3β activity, a key kinase in both DM and AD.
1 context sentence(design, population, supporting numbers)
Summary · context
In rat models, bilateral ICV-STZ administration was used to produce impaired insulin signaling in the brain.
Report a problemFND-2190136407

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

05LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Efficacy outcome
In high-glucose PC12 cells, GLP-1/exendin‑4 protected against reduced viability.
In plain wordsIn cells exposed to high glucose, GLP-1/exendin‑4 protected against loss of cell viability.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCell viability
Study
n: not reported in source
High-glucose PC12 cells
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Our study demonstrated that GLP-1/Ex-4 could exert a protective effect against reduced viability of PC12 cells caused by high glucose and that this protective effect was mediated via the PI3-kinase pathway.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2190136401
06LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Mechanism
In high-glucose PC12 cells, PI3-kinase signaling mediated the protective effect of GLP-1/exendin‑4.
In plain wordsIn cells exposed to high glucose, PI3-kinase signaling mediated protection from GLP-1/exendin‑4.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePI3-kinase mediation
Study
n: not reported in source
High-glucose PC12 cells
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Our study demonstrated that GLP-1/Ex-4 could exert a protective effect against reduced viability of PC12 cells caused by high glucose and that this protective effect was mediated via the PI3-kinase pathway.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2190136402
07LabNot a test of Exenatide (exendin-4) aloneIn vitro (cells)Efficacy outcome
In PC12 cells, GLP-1/exendin‑4 reduced oxidative stress-induced injury.
In plain wordsIn cells, GLP-1/exendin‑4 reduced injury from oxidative stress.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOxidative injury
Study
n: not reported in source
Oxidative stress in PC12 cells
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In addition, GLP-1/Ex-4 ameliorated oxidative stress-induced injury in PC12 cells.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2190136403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.